Versus other vaginal progesterones—
A Decade of Uncompromised Luteal Support, Consistently
Patient Preferred
Click on the Lead Author’s name for more information about each study.
Lead Author |
Comparable Pregnancy Outcomes |
Patient Preferred |
|
Fertil Steril, 2007 |
 |
Not assessed |
|
Fertil Steril, 2007 |
|
|
|
Reprod BioMed Online, 2007 |
|
Not assessed |
|
Eur J Obstet Gynecol Reprod Biol, 2002 |
|
|
|
ESHRE,* 2000 |
|
Not assessed |
|
Fertil Steril, 2000 |
|
Not assessed |
| *ESHRE=European Society for Human Reproduction and Embryology. |
References: 1. Doody K, Shamma N, Paulson R, Bayer S, Blake E, Yankov V. Endometrin® for luteal phase support in a randomized, controlled, open-label, prospective IVF clinical trial using a combination of Menopur® and Bravelle®. Fertil Steril. 2007;87(Suppl 2):S24. Abstract P-34. 2. Simunic V, Tomic V, Tomic J, Nizic D. Comparative study of the efficacy and tolerability of two vaginal progesterone formulations, Crinone 8% gel and Utrogestan capsules, used for luteal support. Fertil Steril. 2007;87:83–87. 3. Geber S, Moreira AC, de Paula SO, Sampaio M. Comparison between two forms of vaginally administered progesterone for luteal phase support in assisted reproduction cycles. Reprod BioMed Online. 2007;14:155–158. Available at: rbmonline.com/Article/2551. 4. Ludwig M, Schwartz P, Babahan B, et al. Luteal phase support using either Crinone® 8% or Utrogest®: results of a prospective, randomized study. Eur J Obstet Gynecol Reprod Biol. 2002;103:48–52. 5. Alper MM, Penzias AS. Crinone® offers excellent implantation rates in patients undergoing IVF. Paper presented at the 16th Annual Meeting of the European Society for Human Reproduction & Embryology; June 2000; Bologna, Italy. Abstract P-059. 6. Williams SC, Donahue J, Muasher SJ. Vaginal progesterone thereapy during programmed cycles for frozen embryo transfer: an analysis of serum progesterone levels and pregnancy rates. Fertil Steril. 2000;74(suppl 1):S209. Abstract P-363.
Important Safety Information
The most common side effects of CRINONE (progesterone gel) 8% include breast enlargement, constipation, somnolence, nausea, headache, and perineal pain. CRINONE 8% is contraindicated in patients with active, or a history of, thrombophlebitis or thromboembolic disorders, patients who have known sensitivity to CRINONE 8%, missed abortion, undiagnosed vaginal bleeding, liver dysfunction or disease, and known or suspected malignancy of the breast or genital organs. Should any of the earliest manifestations of thrombotic disorders occur, the drug should be discontinued immediately. No adequate evidence is available to show that progesterone and progestins are effective in preventing miscarriage in women with a history of recurrent spontaneous pregnancy losses. The pretreatment physical exam should include special reference to breast and pelvic organs as well as a Papanicolaou smear. Nonfunctional causes of breakthrough bleeding should be considered, and for undiagnosed vaginal bleeding, diagnostic measures should be undertaken. Special care should be taken with patients who have conditions that may be influenced by fluid retention, those who have a history of psychic depression, and those with diabetes.